MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why SHPH Stock slipped -0.19% Today — RQD Quant Desk Flash
$5.23 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.22
Shuttle Pharmaceuticals Holdings Inc. (SHPH) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $24.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.22 (-0.22%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SHPH)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY SHPH SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 58 (BULLISH MOMENTUM)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$5.33-4.7% Next Q
54
Q2 (-2Q)Grade C-$5.08-4.3% Next Q
51
Q3 (-1Q)Grade D$4.86+7.6% Next Q
49
CurrentGrade D$5.23-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SHPH Turnaround Squeeze
While SHPH currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.18) and Max Pain ($5.49) forces dealer call-delta covering toward $46.62.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SHPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SHPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SHPH Stock slipped -0.19% Today — RQD Quant Desk Flash
Shuttle Pharmaceuticals Holdings Inc. (SHPH) slipped -0.19% to $5.23, trading at 6% of its 52-week range ($2.58 – $44.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($2.58 – $44.4) with RSI-14 at 58 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.23 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SHPH Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SHPH)
- ✓Walkthrough of SHPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SHPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.22%▲ ASCENDING CHANNEL
2026-10-30O $5.35H $5.41L $4.80C $5.23VOL 20.5K
RES: $6.14SUP: $3.36SMA50: $4.18SMA200: $7.05
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SHPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SHPH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SHPH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SHPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SHPH)
Health Care Rank #460 of 1016
⚔️ IMMP vs SHPH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SHPH vs. IMMP, MIRA, CRVO, CELU)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Shuttle Pharmaceuticals Holdings Inc. (SHPH) ranks #460 by composite RQD confidence (46/100, grade D) and #819 by equity capitalization ($24.9M). Within this direct 5-issuer industry benchmark cohort, SHPH leads on earnings valuation at N/A trailing P/E, while SHPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with SHPH at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SHPH
ACTIVE
Shuttle Pharmaceuticals Holdings Inc. | D | 46/100 | — | — | -35.0% | -0.19% | $24.9M | Benchmark Subject |
| IMMP Immutep Limited | C- | 60/100 | — | — | — | +0.30% | $24.5M | /immp-vs-shph → |
| MIRA MIRA Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.79% | $24.0M | /mira-vs-shph → |
| CRVO CervoMed Inc. | E | 29/100 | — | — | -35.0% | -20.81% | $26.5M | /crvo-vs-shph → |
| CELU Celularity Inc. (Class A) | E | 34/100 | — | 24.4% | -35.0% | -9.66% | $27.6M | /celu-vs-shph → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757499In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.7M, operating cash flow of -$9.5M, and free cash flow of -$9.5M (-29.4% YoY). On the balance sheet, SHPH closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$11.7M | -$9.5M | -$9.5M | $10.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$9.1M | -$7.3M | -$7.3M | $2.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$6.6M | -$5.6M | -$5.6M | — | — |
3. SHPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $5.23 (-0.19% 1D, market cap $24.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SHPH ranks #460 in composite RQD confidence.
How does SHPH compare to IMMP and MIRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SHPH carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $24.0M). Among the 5-stock peer group, SHPH leads on earnings multiple (N/A) while SHPH leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SHPH?
Per SHPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757499), Shuttle Pharmaceuticals Holdings Inc. generated $0 in revenue, -$11.7M in net income, and -$9.5M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SHPH trading relative to its 50-day, 200-day, and 52-week technical levels?
SHPH last traded at $5.23 (-0.19% on volume of 5,572 shares), positioning the stock +25.12% above its 50-day simple moving average ($4.18) and -25.82% below its 200-day simple moving average ($7.05). Across its 52-week range of $2.58 to $44.40, SHPH sits at the 6.3% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.58 to $5.88).
SHPH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SHPH stock moving today?
Why SHPH Stock slipped -0.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.